Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1999 Apr;54(4):301–307. doi: 10.1136/thx.54.4.301

Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma

H Guite 1, R Dundas 1, P Burney 1
PMCID: PMC1745462  PMID: 10092690

Abstract

BACKGROUND—Patients with asthma have an increased risk of death from causes other than asthma. A study was undertaken to identify whether severity of asthma, its treatment, or associated co-morbidity were associated with increased risk of death from other causes.
METHODS—Eighty five deaths from all causes occurring within three years of discharge from hospital in a cohort of 2242 subjects aged 16-64 years admitted for asthma were compared with a random sample of 61 controls aged <45 years and 61 aged ⩾45 years from the same cohort.
RESULTS—Deaths from asthma were associated with a history of clinically severe asthma (OR 6.29 (95% CI 1.84 to 21.52)), chest pain (OR 3.78 (95% CI 1.06 to 13.5)), biochemical or haematological abnormalities at admission (OR 4.12 (95% CI 1.36 to 12.49)), prescription of ipratropium bromide (OR 4.04 (95% CI 1.47 to 11.13)), and failure to prescribe inhaled steroids on discharge (OR 3.45 (95% CI 1.35to 9.10)). Deaths from chronic obstructive pulmonary disease (COPD) were associated with lower peak expiratory flow rates (OR 2.56(95% CI 1.52 to 4.35) for each 50 l/min change), a history of smoking (OR 5.03 (95% CI 1.17 to 21.58)), prescription of ipratropium bromide (OR 7.75 (95% CI 2.21 to 27.14)), and failure to prescribe inhaled steroids on discharge (OR 3.33 (95% CI 0.95 to 11.10)). Cardiovascular deaths were more common among those prescribed ipratropium bromide on discharge (OR 3.55 (95% CI 1.05 to 11.94)) and less likely in those admitted after an upper respiratory tract infection (OR 0.21 (95% CI 0.05 to 0.95)). Treatment with ipratropium bromide at discharge was associated with an increased risk of death from asthma even after adjusting for peak flow, COPD and cardiovascular co-morbidity, ever having smoked, and age at onset of asthma.
CONCLUSIONS—Prescription of inhaled steroids on discharge is important even for those patients with co-existent COPD and asthma. Treatment with ipratropium at discharge is associated with increased risk of death from asthma even after adjustment for a range of markers of COPD. These results need to be tested in larger studies.



Full Text

The Full Text of this article is available as a PDF (121.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonelli Incalzi R., Fuso L., De Rosa M., Forastiere F., Rapiti E., Nardecchia B., Pistelli R. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997 Dec;10(12):2794–2800. doi: 10.1183/09031936.97.10122794. [DOI] [PubMed] [Google Scholar]
  2. BULLEN S. S. Correlation of clinical and autopsy findings in 176 cases of asthma. J Allergy. 1952 May;23(3):193–203. doi: 10.1016/0021-8707(52)90017-8. [DOI] [PubMed] [Google Scholar]
  3. Barnes N. C. Inhaled steroids in COPD. Lancet. 1998 Mar 14;351(9105):766–767. doi: 10.1016/s0140-6736(98)22011-3. [DOI] [PubMed] [Google Scholar]
  4. Bourbeau J., Rouleau M. Y., Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax. 1998 Jun;53(6):477–482. doi: 10.1136/thx.53.6.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burrows B. The natural history of asthma. J Allergy Clin Immunol. 1987 Sep;80(3 Pt 2):373–377. doi: 10.1016/0091-6749(87)90052-2. [DOI] [PubMed] [Google Scholar]
  6. Charlson M. E., Pompei P., Ales K. L., MacKenzie C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8. [DOI] [PubMed] [Google Scholar]
  7. Donahue J. G., Weiss S. T., Livingston J. M., Goetsch M. A., Greineder D. K., Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997 Mar 19;277(11):887–891. [PubMed] [Google Scholar]
  8. Ernst P., Spitzer W. O., Suissa S., Cockcroft D., Habbick B., Horwitz R. I., Boivin J. F., McNutt M., Buist A. S. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA. 1992 Dec 23;268(24):3462–3464. [PubMed] [Google Scholar]
  9. Guite H. F., Burney P. G. Accuracy of recording of deaths from asthma in the UK: the false negative rate. Thorax. 1996 Sep;51(9):924–928. doi: 10.1136/thx.51.9.924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ishihara K., Hasegawa T., Okazaki M., Katakami N., Sakamoto H., Umeda B., Nakai H. Long-term follow-up of patients with a history of near fatal episodes; can inhaled corticosteroids reduce the risk of death from asthma? Intern Med. 1995 Feb;34(2):77–80. doi: 10.2169/internalmedicine.34.77. [DOI] [PubMed] [Google Scholar]
  11. Lacronique J., Renon D., Georges D., Henry-Amar M., Marsac J. High-dose beclomethasone: oral steroid-sparing effect in severe asthmatic patients. Eur Respir J. 1991 Jul;4(7):807–812. [PubMed] [Google Scholar]
  12. Lange P., Ulrik C. S., Vestbo J. Mortality in adults with self-reported asthma. Copenhagen City Heart Study Group. Lancet. 1996 May 11;347(9011):1285–1289. doi: 10.1016/s0140-6736(96)90937-x. [DOI] [PubMed] [Google Scholar]
  13. Mackenbach J. P., Kunst A. E., Lautenbach H., Bijlsma F., Oei Y. B. Competing causes of death: an analysis using multiple-cause-of-death data from The Netherlands. Am J Epidemiol. 1995 Mar 1;141(5):466–475. doi: 10.1093/oxfordjournals.aje.a117449. [DOI] [PubMed] [Google Scholar]
  14. Mann K. V., Leon A. L., Tietze K. J. Use of ipratropium bromide in obstructive lung disease. Clin Pharm. 1988 Sep;7(9):670–680. [PubMed] [Google Scholar]
  15. Markowe H. L., Bulpitt C. J., Shipley M. J., Rose G., Crombie D. L., Fleming D. M. Prognosis in adult asthma: a national study. Br Med J (Clin Res Ed) 1987 Oct 17;295(6604):949–952. doi: 10.1136/bmj.295.6604.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Massey K. L., Gotz V. P. Ipratropium bromide. Drug Intell Clin Pharm. 1985 Jan;19(1):5–12. doi: 10.1177/106002808501900102. [DOI] [PubMed] [Google Scholar]
  17. Paggiaro P. L., Dahle R., Bakran I., Frith L., Hollingworth K., Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998 Mar 14;351(9105):773–780. doi: 10.1016/s0140-6736(97)03471-5. [DOI] [PubMed] [Google Scholar]
  18. Persson C., Bengtsson C., Lapidus L., Rybo E., Thiringer G., Wedel H. Peak expiratory flow and risk of cardiovascular disease and death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Am J Epidemiol. 1986 Dec;124(6):942–948. doi: 10.1093/oxfordjournals.aje.a114483. [DOI] [PubMed] [Google Scholar]
  19. Ryan G., Musk A. W., Perera D. M., Stock H., Knight J. L., Hobbs M. S. Risk factors for death in patients admitted to hospital with asthma: a follow-up study. Aust N Z J Med. 1991 Oct;21(5):681–685. doi: 10.1111/j.1445-5994.1991.tb01370.x. [DOI] [PubMed] [Google Scholar]
  20. Sheiner L. B., Easterling M. J., Mozes B., Brown A. Laboratory data predicts survival post hospitalization. J Clin Epidemiol. 1991;44(12):1387–1403. doi: 10.1016/0895-4356(91)90100-n. [DOI] [PubMed] [Google Scholar]
  21. Suissa S., Hemmelgarn B., Blais L., Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1598–1602. doi: 10.1164/ajrccm.154.6.8970341. [DOI] [PubMed] [Google Scholar]
  22. Toogood J. H., Baskerville J., Jennings B., Lefcoe N. M., Johansson S. A. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis. 1984 May;129(5):723–729. doi: 10.1164/arrd.1984.129.5.723. [DOI] [PubMed] [Google Scholar]
  23. Torén K., Lindholm N. B. Do patients with severe asthma run an increased risk from ischaemic heart disease? Int J Epidemiol. 1996 Jun;25(3):617–620. doi: 10.1093/ije/25.3.617. [DOI] [PubMed] [Google Scholar]
  24. Weiner P., Weiner M., Azgad Y., Zamir D. Inhaled budesonide therapy for patients with stable COPD. Chest. 1995 Dec;108(6):1568–1571. doi: 10.1378/chest.108.6.1568. [DOI] [PubMed] [Google Scholar]
  25. Weiss S. T., Segal M. R., Sparrow D., Wager C. Relation of FEV1 and peripheral blood leukocyte count to total mortality. The Normative Aging Study. Am J Epidemiol. 1995 Sep 1;142(5):493–503. doi: 10.1093/oxfordjournals.aje.a117665. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES